Skip to main content

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.